Holland Gary N, Vaudaux Jean D, Jeng Samuel M, Yu Fei, Goldenberg David T, Folz Ina-Caren, Cumberland William G, McCannel Colin A, Helm Craig J, Hardy W David
Ocular Inflammatory Disease Center, Jules Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.
Am J Ophthalmol. 2008 Jan;145(1):5-11. doi: 10.1016/j.ajo.2007.09.023.
To identify factors related to variations in the appearance of untreated AIDS-related cytomegalovirus (CMV) retinitis in severely immunodeficient individuals before the availability of highly active antiretroviral therapy (HAART) and to draw inferences regarding early events in the natural history of CMV retinitis based on clinical findings.
Retrospective, observational case series.
We evaluated a series of 100 adult patients with AIDS and newly diagnosed CMV retinitis before the HAART era who were not being treated with specific anti-CMV therapy. Demographic factors, ophthalmic findings, and the influence of drug therapy (zidovudine, acyclovir) on lesion characteristics were evaluated. Lesion border opacity was scored using a four-point scale of severity.
Lesions could be categorized by type (fulminant/edematous or indolent/granular) in only 66% of eyes. Severe lesion border opacity (4+) was related to presence of zone 1 lesions (P = .032) and greater extent of disease (P = .004). Acyclovir use was associated with less severe opacity (P = .029) and less zone 1 involvement (P = .016). Early lesions were adjacent to vessels in 73% of eyes; the fovea was involved in 13% of eyes.
Lesion location and drug use that affects virus activity may influence the severity of lesion border opacity, a measure that may be more useful than lesion type in future clinical studies of CMV retinitis. In contrast to earlier concepts, CMV retinitis does not seem to be a fovea-sparing disease. Findings in this study can serve as a reference for investigations into possible changes in CMV retinitis since the introduction of HAART.
在高效抗逆转录病毒治疗(HAART)出现之前,确定与严重免疫缺陷个体中未经治疗的艾滋病相关巨细胞病毒(CMV)视网膜炎外观变化相关的因素,并根据临床发现推断CMV视网膜炎自然史中的早期事件。
回顾性观察病例系列。
我们评估了100例在HAART时代之前新诊断为CMV视网膜炎且未接受特异性抗CMV治疗的成年艾滋病患者。评估了人口统计学因素、眼科检查结果以及药物治疗(齐多夫定、阿昔洛韦)对病变特征的影响。使用四点严重程度量表对病变边界不透明度进行评分。
仅66%的眼睛中的病变可按类型(暴发性/水肿性或惰性/颗粒性)分类。严重的病变边界不透明度(4+)与1区病变的存在(P = 0.032)和疾病范围更大(P = 0.004)相关。使用阿昔洛韦与较轻的不透明度(P = 0.029)和较少的1区受累(P = 0.016)相关。73%的眼睛中早期病变与血管相邻;13%的眼睛中黄斑受累。
影响病毒活性的病变位置和药物使用可能会影响病变边界不透明度的严重程度,在未来CMV视网膜炎的临床研究中,这一指标可能比病变类型更有用。与早期概念相反,CMV视网膜炎似乎不是一种不累及黄斑的疾病。本研究结果可作为自引入HAART以来CMV视网膜炎可能变化研究的参考。